Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vitamin supplement boost male fertility and pregnancy odds?

NCT ID NCT03337360

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests whether Impryl, a nutritional supplement with B vitamins and zinc, can increase the chance of an ongoing pregnancy in couples where the male partner has subfertility. About 1,200 couples will take either Impryl or a placebo while starting fertility treatments like IUI or IVF. The main goal is to see if the supplement improves the ongoing pregnancy rate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Impryl, a nutritional supplement containing B vitamins, zinc, and other ingredients
What this could lead to
If it works, Impryl could offer a simple, non-invasive way to improve pregnancy chances for couples facing male subfertility.
What could go wrong
The trial is large but the supplement may not outperform placebo, and results depend on many factors beyond the supplement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,200 people

The number who actually took part.

Started

Apr 2018

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Couples with failure to conceive for at least 12 months and starting with EM or Couples starting with 1st/ 2nd/3rd cycle of IUI (with/without ovarian stimulation) or Couples starting with 1st/ 2nd/3rd cycle of IVF/ICSI Furthermore: * Male with age 18-50 years * Female partner with age 18-43 years * Willing and able to give informed consent Exclusion Criteria: * Planned or performed diagnostic testicular biopsy (TESE) or percutaneous epididymal sperm aspiration (PESA) * Use of donor-, cryopreserved- or electro-ejaculated semen * Ovulation induction (OI) without IUI * IVF for an absolute tubal factor * Embryo-transfers after cryopreservation * Embryo-transfer after pre-implantation genetic diagnosis * Known genetic abnormalities related to infertility * Known urological abnormality such as a varicocele or bilateral cryptorchism * Use of other vitamin supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Male subfertility are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

male infertility

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Male subfertility

Contacts and locations

Locations

  • Albert Schweitzer ziekenhuis

    Dordrecht, 3318AT, Netherlands

  • Amphia ziekenhuis

    Breda, 4818CK, Netherlands

  • Bernhoven Ziekenhuis

    Uden, 5400AS, Netherlands

  • Bravis Ziekenhuis

    Roosendaal, 4708AE, Netherlands

  • Catharina Ziekenhuis Eindhoven

    Eindhoven, 5623EJ, Netherlands

  • Elisabeth-TweeSteden Ziekenhuis

    Tilburg, 5022GC, Netherlands

  • Fertiliteitscentrum Voorburg

    Voorburg, Gelderland, Netherlands

  • Franciscus Gasthuis en Vlietland

    Rotterdam, 3045PM, Netherlands

  • Gelre Ziekenhuizen

    Apeldoorn, 7334DZ, Netherlands

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch, 5200ME, Netherlands

  • Maasstad ziekenhuis

    Rotterdam, 3079DZ, Netherlands

  • Maasziekenhuis Pantein

    Boxmeer, 5835DV, Netherlands

  • Medisch Centrum Kinderwens

    Leiderdorp, Netherlands

  • Máxima Medisch Centrum

    Veldhoven, 5504DB, Netherlands

  • Nij Barrahus

    Wolvega, Netherlands

  • Nij Geertgen

    Elsendorp, 5424SM, Netherlands

  • Nij Linge

    Gorinchem, 4207HG, Netherlands

  • Radboudumc

    Nijmegen, 6500HB, Netherlands

  • Rijnstate

    Arnhem, 6815AD, Netherlands

  • Slingeland Ziekenhuis

    Doetinchem, 7002BL, Netherlands

  • Treant ziekenhuis Scheper

    Emmen, 7824AA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.